

Anti-Human CD19 (A3-B1)



| | | | |
|------------------|----------------|----------|------------|
| PURE | 19PUI | 1 mg | 1 mg/ml |
| PURE | 19PUI-OIMG | 100 test | 1 µg/test |
| FITC | 19FI-100T | 100 test | 20 µL/test |
| PE | 19PEI-100T | 100 test | 20 µL/test |
| PerCP-Cyanine5.5 | 19PPC5.5I-100T | 100 test | 5 µL/test |
| APC | 19AI-100T | 100 test | 20 µL/test |
| APC-C750 | 19AC750-100T | 100 test | 5 µL/test |

RUO

1. PRODUCT DESCRIPTION

Clone: A3-B1;
Isotype: IgG2a;
Tested application: flow cytometry;
Immunogen: The anti-CD19 monoclonal antibody derives from human tonsil;
Species reactivity: Human;
Storage instruction: store in the dark at 2-8 °C;
Storage buffer: aqueous buffered solution containing protein stabilizer and 0.09% sodium azide (NaN₃);
Recommended usage: Immunostep's CD19, clone A3-B1 is a monoclonal antibody intended for the identification and enumeration of human B cells using flow cytometry. This reagent is effective for direct immunofluorescence staining of human tissue for flow cytometric analysis using 1 test for 10⁶ cells;
Presentation: liquid;
Source: Supernatant proceeding from an in vitro cell culture of a cell hybridoma;
Purification: Affinity chromatography;
Other names: B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12, B4;
Gene ID: 930;
Molecular weight: Ig superfamily, type I transmembrane glycoprotein, 95 kDa.

2. ANTIGEN DETAILS

Large description: The monoclonal antibody is directed against the CD19- antigen (B4-antigen), which is expressed on human B lymphocytes. The monoclonal antibody is B lineage-specific and reacts with early B-cell precursors, pre-pre-B-cells, pre-B- cells, B-cells, intermediate B-cells, mature B-cells and some plasmacytoid cells, also reacts with pre-B-cell- lines, B lymphoblastoid cell-lines and Burkitt cell- lines, and with 50% of myeloma cell-lines. Plasma cells were found to be negative.⁽¹⁻⁴⁾

3. WARRANTY

Warranted only to conform to the quantity and contents stated on the label or in the product labelling at the time of delivery to the customer. Immunostep disclaims hereby other warranties.

Immunostep's sole liability is limited to either the replacement of the products or refund of the purchase price.

4. ADDITIONAL INFORMATION

For research use only. Not for diagnostic use.

Not for resale. Immunostep will not be responsible of violations that may occur with the use of this product. Any use of this product other than the specified in this document is strictly prohibited.

Unless otherwise indicated by Immunostep by written authorization, this product is intended for research only and is not to be used for any other purpose, including without limitation, for human or animal diagnostic, therapeutic or commercial purposes.

Please, refer to www.immunostep.com technical support for more information.

5. REFERENCES

1. Pezzutto A, Dorken B, Rabinovitch PS, Ledbetter JA, Moldenhauer G, Clark EA. CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. *J Immunol*1987 May 1;138(9):2793-9.
2. Sato S, Ono N, Steeber DA, Pisetsky DS, Tedder TF. CD19 regulates B lymphocyte signaling thresholds critical for the development of B-1 lineage cells and autoimmunity. *J Immunol*1996 Nov 15;157(10):4371-8.
3. Carter RH, Doody GM, Bolen JB, Fearon DT. Membrane IgM-induced tyrosine phosphorylation of CD19 requires a CD19 domain that mediates association with components of the B cell antigen receptor complex. *J Immunol*1997 Apr 1;158(7):3062-9.
4. Braylan RC, Orfao A, Borowitz MJ, Davis BH. Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting. *Cytometry*2001 Feb 15;46(1):23-7.

6. EXPLANATION OF SYMBOLS



Form



Catalog reference



Contains sufficient for <n> test



Quantity per test



Regulatory Status



Research Use Only



Manufacturer

7. MANUFACTURED BY:



IMMUNOSTEP S.L.

Address: Avda. Universidad de Coimbra, s/n
Cancer Research Center (C.I.C)
Campus de Unamuno
37007 Salamanca (Spain)

Tel./fax: (+34) 923 294 827

E-mail: info@immunostep.com
www.immunostep.com